Tumor suppressor genes, treatments, and survival in US veterans with prostate cancer
TSG alterations were associated with inferior OS in veterans with mHSPC. In this real-world observational study, ARPI-based combination therapy in veterans with TSG alterations was associated with the longest survival.
Authors
- Carley Pickett
- E Knoche
- Matthew B. Rettig (ORCID: https://orcid.org/0000-0002-7394-3056)
- Ruben Raychaudhuri (ORCID: https://orcid.org/0000-0001-6587-4954)
- Jason M. Doherty (ORCID: https://orcid.org/0000-0003-3142-5805)
- Daniel B. Eaton (ORCID: https://orcid.org/0000-0001-9819-2159)
- Kara N. Maxwell
- R Bruce Montgomery
- Joshua Gruber
- Martin W Schoen
- Krishny Karunanandaa
Institutions
- Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa (ZA)
- University of California, Los Angeles (US)
- Washington University in St. Louis (US)
- Fred Hutch Cancer Center (US)
- VA Puget Sound Health Care System (US)
- St. Louis VA Medical Center (US)
- Philadelphia VA Medical Center (US)
- VA Greater Los Angeles Healthcare System (US)
- Saint Louis University (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2026-02-03
- DOI
- https://doi.org/10.1093/oncolo/oyag033
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00